Literature DB >> 8339731

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.

M Granowska1, K E Britton, S J Mather, D G Lowe, D Ellison, J Bomanji, J Burchell, J Taylor-Papadimitriou, C R Hudson, J H Shepherd.   

Abstract

Radioimmunoscintigraphy (RIS) with technetium-99m labelled SM3, a monoclonal antibody reacting with a polymorphic epithelial mucin glycoprotein core antigen, is evaluated. No adverse effects or thyroid uptake were observed. Studies in 45 patients (one twice) had a sensitivity for gynaecological malignancy of 100% (35/35) and a specificity of 73% (8/11), giving an overall accuracy of 93% (43/46). These results have led to the routine adoption of 99mTc RIS in the management of patients suspected of or having primary or recurrent gynaecological cancer.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8339731     DOI： 10.1007/bf00175160

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  28 in total

1.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.

Authors:  A Girling; J Bartkova; J Burchell; S Gendler; C Gillett; J Taylor-Papadimitriou
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

Review 2.  Radiolabelled monoclonal antibodies in oncology. I. Technical aspects.

Authors:  K E Britton; M Granowska; S J Mather
Journal:  Nucl Med Commun       Date:  1991-01       Impact factor: 1.690

3.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

4.  Pitfalls in interpretation of computed tomography prior to second-look laparotomy in patients with ovarian cancer.

Authors:  A R Calkins; F B Stehman; J L Wass; L R Smirz; J H Ellis
Journal:  Br J Radiol       Date:  1987-10       Impact factor: 3.039

5.  Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer.

Authors:  J G Tibben; L F Massuger; R A Claessens; C P Schijf; K Y Pak; S P Strijk; P Kenemans; F H Corstens
Journal:  Nucl Med Commun       Date:  1992-12       Impact factor: 1.690

6.  Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery.

Authors:  M Granowska; S J Mather; K E Britton
Journal:  Int J Rad Appl Instrum B       Date:  1991

7.  Use of indium-111-labeled OC-125 monoclonal antibody in the detection of ovarian cancer.

Authors:  R E Hunter; P Doherty; T W Griffin; M Gionet; D J Hnatowich; J A Bianco; M B Dillon
Journal:  Gynecol Oncol       Date:  1987-07       Impact factor: 5.482

8.  Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody.

Authors:  F Crippa; G L Buraggi; E Di Re; M Gasparini; E Seregni; S Canevari; M Gadina; M Presti; A Marini; E Seccamani
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours.

Authors:  M Granowska; S J Mather; T Jobling; M Naeem; J Burchell; J Taylor-Papadimitriou; J Shepherd; K E Britton
Journal:  Int J Biol Markers       Date:  1990 Apr-Jun       Impact factor: 3.248

10.  Role of ultrasound in the management of ovarian carcinoma.

Authors:  O Khan; D O Cosgrove; E Wiltshaw; C Bland; V R McCready
Journal:  J R Soc Med       Date:  1983-10       Impact factor: 18.000
View more
  6 in total

1.  Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.

Authors:  M A Stalteri; S J Mather
Journal:  Eur J Nucl Med       Date:  1996-02

Review 2.  Recent trends in antibody-based oncologic imaging.

Authors:  Sukhwinder Kaur; Ganesh Venktaraman; Maneesh Jain; Shantibhusan Senapati; Pradeep K Garg; Surinder K Batra
Journal:  Cancer Lett       Date:  2011-10-20       Impact factor: 8.679

3.  Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences.

Authors:  C Alexander; C E Villena-Heinsen; L Trampert; S Lung-Kurt; E Oberhausen; C M Kirsch; W Schmidt
Journal:  Eur J Nucl Med       Date:  1995-07

4.  99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection.

Authors:  L Biassoni; M Granowska; M J Carroll; S J Mather; R Howell; D Ellison; F A MacNeill; C A Wells; R Carpenter; K E Britton
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-CA125 monoclonal antibody.

Authors:  H Sakahara; M Hosono; H Kobayashi; Z Yao; T Saga; S Yano; K Endo; T Mori; J Konishi
Journal:  Jpn J Cancer Res       Date:  1996-06

6.  Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe.

Authors:  T E Ind; M Granowska; K E Britton; G Morris; D G Lowe; C N Hudson; J H Shepherd
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.